Proteinuria: abate or applaud abatacept in proteinuric kidney disease?

Jochen Reiser; Nada Alachkar

doi:10.1038/nrneph.2013.276

Proteinuria: abate or applaud abatacept in proteinuric kidney disease?

Jochen Reiser
, Nada Alachkar

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.

Original language	English (US)
Pages (from-to)	128-130
Number of pages	3
Journal	Nature Reviews Nephrology
Volume	10
Issue number	3
DOIs	https://doi.org/10.1038/nrneph.2013.276
State	Published - Mar 2014
Externally published	Yes

ASJC Scopus subject areas

Nephrology

Access to Document

10.1038/nrneph.2013.276

Cite this

@article{4d1b8a2196a3460988e79483ad7af814,

title = "Proteinuria: abate or applaud abatacept in proteinuric kidney disease?",

abstract = "T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.",

author = "Jochen Reiser and Nada Alachkar",

note = "Funding Information: M. Tonelli is supported by a Government of Canada research chair in the optimal care of people with chronic kidney disease.",

year = "2014",

month = mar,

doi = "10.1038/nrneph.2013.276",

language = "English (US)",

volume = "10",

pages = "128--130",

journal = "Nature Reviews Nephrology",

issn = "1759-5061",

publisher = "Nature Research",

number = "3",

}

TY - JOUR

T1 - Proteinuria

T2 - abate or applaud abatacept in proteinuric kidney disease?

AU - Reiser, Jochen

AU - Alachkar, Nada

N1 - Funding Information: M. Tonelli is supported by a Government of Canada research chair in the optimal care of people with chronic kidney disease.

PY - 2014/3

Y1 - 2014/3

N2 - T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.

AB - T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.

UR - https://www.scopus.com/pages/publications/84906564596

UR - https://www.scopus.com/pages/publications/84906564596#tab=citedBy

U2 - 10.1038/nrneph.2013.276

DO - 10.1038/nrneph.2013.276

M3 - Review article

C2 - 24375054

AN - SCOPUS:84906564596

SN - 1759-5061

VL - 10

SP - 128

EP - 130

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

IS - 3

ER -

Proteinuria: abate or applaud abatacept in proteinuric kidney disease?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this